Search

Displaying results 8341 - 8350 of 8547 in total
  1. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  2. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib has a monoisotopic molecular weight of 467.25 Da.

  3. Drug

    Tegtociclib

    go.drugbank.com/drugs/DB21635
    Investigational

    Tegtociclib has a monoisotopic molecular weight of 404.22 Da.

  4. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat has a monoisotopic molecular weight of 608.14 Da.

  5. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    RGN6024, also known as RGN-6024 or RGNi6024, is a synthetic small-molecule tubulin destabilizer from Reglagene. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  6. Drug

    Razuprotafib

    go.drugbank.com/drugs/DB16353
    Investigational

    Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.

  7. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.

  8. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

  9. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication

  10. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.